content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="margin: 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on December 21, 2023</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8 </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>UNDER </I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>THE SECURITIES ACT OF 1933</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>
  
  <P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>INMED PHARMACEUTICALS
  INC. </B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
  charter)</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; font-size: 10pt; text-align: center; width: 49%"><FONT STYLE="font-size: 10pt"><B>British
      Columbia </B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom; font-size: 10pt; width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; font-size: 10pt; text-align: center; width: 49%"><FONT STYLE="font-size: 10pt"><B>98-1428279</B></FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction of</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>incorporation or organization)</B>&nbsp;</P></TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S Employer</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B>&nbsp;</P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suite 310 &ndash; 815 West Hastings Street</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Vancouver, British Columbia V6C 1B4</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Canada</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (604) 669-7207</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address, including zip code and telephone
  number, including area code, of registrant&rsquo;s principal executive offices)</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>InMed Pharmaceuticals Inc. Amended 2017 Stock
  Option Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Full title of the plan) </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registered Agent Solutions, Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1100 H Street NW</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suite 840</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20005</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (888) 705-7274</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name, address, including zip code, and telephone
  number, including area code, of agent for service)</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies to: </I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Eric A. Adams</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Executive Officer</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>InMed Pharmaceuticals Inc.</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suite 310 &ndash; 815 West Hastings Street</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Vancouver, British Columbia V6C 1B4</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Canada</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (604) 669-7207</B></P></TD>
      <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Brian P. Fenske</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Norton Rose Fulbright US LLP </B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1301 McKinney, Suite 5100 </B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Houston, Texas 77010 </B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (713)&nbsp;651-5557 </B></P></TD></TR>
    </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &ldquo;large
  accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company&rdquo;
  in in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 19%"><FONT STYLE="font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
      <TD STYLE="width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
      <TD STYLE="width: 32%"><FONT STYLE="font-size: 10pt">Accelerated&nbsp;filer</FONT></TD>
      <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
      <TD>&#9746;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
  has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
  to Section 7(a)(2)(B) of the Securities Act. &#9744;</P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On December 19, 2023, the board of directors of
  InMed Pharmaceuticals Inc. (the &ldquo;Company&rdquo;), approved the reservation of additional 700,000 shares of common stock, without
  par value (the &ldquo;Common Shares&rdquo;), for allotment under the InMed Pharmaceuticals Inc. Amended 2017 Stock Option Plan (the &ldquo;2017
  Stock Option Plan&rdquo;).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Registration Statement on Form S-8 (this
  &ldquo;Registration Statement&rdquo;) is being filed by the Company to register the additional Common Shares. These shares are in addition
  to the 51,633 Common Shares that may be issued under the 2017 Stock Option Plan pursuant to the Company&rsquo;s Registration Statements
  on Form S-8 (File No.&nbsp;333-268356) filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) on November 14,
  2022, Form S-8 (File No. 333-253912) filed with the Commission on March 5, 2021, and Form S-8 (File No.&nbsp;333-260323) filed with the
  Commission on October 18, 2021 (collectively, the &ldquo;Prior Registration Statements&rdquo;). Pursuant to General Instruction E to
  Form S-8 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), the contents of the Prior Registration Statements
  are incorporated by reference into this Registration Statement, except to the extent supplemented, amended and superseded by the information
  set forth herein.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3. Incorporation of Documents by Reference. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except to the extent that information is deemed furnished and not
  filed pursuant to securities laws and regulations, the following documents, which have been previously filed with the Commission, are
  incorporated by reference into this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>our
                                              Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390023080842/f10k2023_inmedpharma.htm" STYLE="-sec-extract: exhibit">Form
                                              10-K</A> for the fiscal year ended June 30, 2023, filed with the SEC on September 29, 2023 and Amendment No.1 thereto on <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390023097753/f10k2023a1_inmedphar.htm" STYLE="-sec-extract: exhibit">Form 10-K/A</A> filed with the SEC on December 21, 2023;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>our
                                              Definitive Proxy Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000101376223007274/def14a1023_inmedpharma.htm" STYLE="-sec-extract: exhibit">Schedule
                                              14A</A>, filed with the SEC on October 27, 2023;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>our
                                              Quarterly Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390023086255/f10q0923_inmedpharma.htm">Form
                                              10-Q</A> for the quarter ended September 30, 2023, filed with the SEC on November 14, 2023;
                                              and</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>our Current Reports on Form 8-K, filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390023058457/ea182104-8k_inmedpharma.htm" STYLE="-sec-extract: exhibit">July 20, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390023059235/ea182247-8k_inmedpharma.htm">July 24, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390023075115/ea184850-8k_inmedpharma.htm">September 8, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390023078887/ea185699-8k_inmedpharma.htm" STYLE="-sec-extract: exhibit">September
                                                                                                                                       25, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390023079147/ea185755-8k_inmedpharm.htm" STYLE="-sec-extract: exhibit">September
                                                                                                                                       25, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390023081108/ea186106-8k_inmedpharm.htm">September 29,
                                                                                                                                       2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000101376223006292/ea187221-8k_inmedpharm.htm">October 24,
                                                                                                                                       2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000101376223007388/ea187408-8k_inmedpharm.htm" STYLE="-sec-extract: exhibit">October
                                                                                                                                       30, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390023082684/ea187670-8k_inmedpharma.htm" STYLE="-sec-extract: exhibit">November
                                                                                                                                       2, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390023087019/ea188382-8k_inmedpharma.htm">November 14,
                                                                                                                                       2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390023090946/ea189237-8k_inmedpharma.htm" STYLE="-sec-extract: exhibit">November
                                                                                                                                       29, 2023</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390023097076/ea190383-8k_inmedpharma.htm">December 20, 2023</A>.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except to the extent that information is deemed furnished and not
  filed pursuant to securities laws and regulations, all documents filed by the Company with the Commission pursuant to Sections 13(a),
  13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, after the date of this Registration Statement and prior to the
  filing of a post-effective amendment that (i) indicates that all securities offered under this Registration Statement have been sold,
  or (ii) deregisters all securities then remaining unsold under this Registration Statement, shall be deemed to be incorporated by reference
  into this Registration Statement and to be a part of this Registration Statement from the date of filing of such documents. In no event,
  however, will any information that we disclose under Item 2.02 or Item 7.01 (and any related exhibits) of any Current Report on Form
  8-K that we may from time to time furnish to the Commission be incorporated by reference into, or otherwise become a part of, this Registration
  Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of this Registration Statement, any statement contained
  in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded to the extent
  that a statement contained herein or in any subsequently filed document which also is or is deemed to be incorporated herein by reference
  modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded,
  to constitute a part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 9%"><FONT STYLE="font-size: 10pt"><B>ITEM&nbsp;8.</B></FONT></TD>
      <TD><FONT STYLE="font-size: 10pt"><B>Exhibits. </B></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; width: 10%"><B>Exhibit&nbsp;No.</B></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
      <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; width: 88%"><B>Exhibit Description</B></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center; white-space: nowrap; vertical-align: top"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000119312520174157/d904092dex31.htm" STYLE="-sec-extract: exhibit">Amended
      and Restated Articles (incorporated by reference to Exhibit 3.1 to the Registrant&rsquo;s Registration Statement on Form S-1 (File
      No. 333-239319), filed on June 19, 2020).</A></FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="text-align: center; white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390021013661/ea136989ex4-2_inmedpharma.htm">InMed
      Pharmaceuticals Inc. Amended 2017 Stock Option Plan (incorporated by reference to Exhibit 4.2 to the Registrant&rsquo;s Registration
      Statement on Form S-8 (File No. 333-253912) filed on March 5, 2021).</A></FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390021013661/ea136989ex4-3_inmedpharma.htm">Form
      of Stock Option Agreement pursuant to InMed Pharmaceuticals Inc. Amended 2017 Stock Option Plan (incorporated by reference to Exhibit
      4.3 to the Registrant&rsquo;s Registration Statement on Form S-8 (File No. 333-253912) filed on March 5, 2021).</A></FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390021036589/ea144036ex4-3_inmedpha.htm">Form
      of Specific Common Share Certificate (incorporated by reference to Exhibit 4.3 to the Company&rsquo;s Form S-1 filed on July 13,
      2021).</A></FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center; white-space: nowrap; vertical-align: top"><FONT STYLE="font-size: 10pt">5.1*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><A HREF="ea190385ex5-1_inmed.htm"><FONT STYLE="font-size: 10pt">Opinion of Norton Rose Fulbright Canada LLP regarding legality of securities being registered.</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="text-align: center; white-space: nowrap; vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center; white-space: nowrap; vertical-align: top">23.1*</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><A HREF="ea190385ex23-1_inmed.htm">Consent of Marcum LLP, Independent Registered Public Accounting Firm.</A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center; white-space: nowrap; vertical-align: top"><FONT STYLE="font-size: 10pt">23.2*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><A HREF="ea190385ex23-2_inmed.htm"><FONT STYLE="font-size: 10pt">Consent of KPMG LLP, Independent Registered Public Accounting Firm.</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center; white-space: nowrap; vertical-align: top"><FONT STYLE="font-size: 10pt">23.3*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><A HREF="ea190385ex5-1_inmed.htm"><FONT STYLE="font-size: 10pt">Consent of Norton Rose Fulbright Canada LLP (contained in Exhibit 5.1).</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center; white-space: nowrap; vertical-align: top"><FONT STYLE="font-size: 10pt">24.1*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><A HREF="#POA"><FONT STYLE="font-size: 10pt">Power of Attorney (included as part of signature page
      to this Registration Statement).</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">107.1*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea190385ex-fee_inmed.htm">Calculation of Filing Fee Tables</A></TD></TR>
    </TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">*</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">Filed herewith. </FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt"></P>
  
  <!-- Field: Page; Sequence: 4; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt">&nbsp;</P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
  Act, InMed Pharmaceuticals Inc., certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
  on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in the City of Vancouver, British Columbia, Canada, on December 21, 2023.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>INMED PHARMACEUTICALS INC.</B></FONT></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR>
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 35%">/s/ <FONT STYLE="font-size: 10pt">Eric A. Adams</FONT></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Eric A. Adams </FONT></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="POA"></A>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">KNOW ALL MEN BY THESE PRESENTS, that each person
  whose signature appears below, the undersigned officers and directors of InMed Pharmaceuticals Inc., hereby severally constitute and
  appoint Eric A. Adams and Jonathan Tegge, and each of them singly (with full power to each of them to act alone), his true and lawful
  attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead,
  and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and
  to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact
  and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done
  in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all
  that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done
  by virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
  Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated on December 21,
  2023.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; width: 40%"><B>Name</B></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
      <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; width: 59%"><B>Title</B></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top">/s/ Eric A. Adams</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">President, Chief Executive Officer and Director</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">Eric A. Adams &nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">(principal executive officer) &nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top">/s/ Jonathan Tegge</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">Interim Chief Financial Officer</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">Jonathan Tegge &nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">(principal financial officer and principal accounting officer) &nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Janet Grove &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">Janet Grove &nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid">/s/ <FONT STYLE="font-size: 10pt">Bryan Baldasare</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
    <TR>
      <TD><FONT STYLE="font-size: 10pt">Bryan Baldasare</FONT></TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top">/s/ Andrew Hull</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">Andrew Hull &nbsp; &nbsp; &nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top">/s/ Nicole Lemerond &nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">Nicole Lemerond &nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"></TD></TR>
    </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 5; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUTHORIZED REPRESENTATIVE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the requirements
  to Section 6(a) of the Securities Act of 1933, the undersigned has signed this registration statement solely in the capacity of the duly
  authorized representative of InMed Pharmaceuticals Inc. in the United States on December 21, 2023.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 35%">/s/ <FONT STYLE="font-size: 10pt">Andrew Hull</FONT></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Andrew Hull</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
  
  <!-- Field: Page; Sequence: 6; Options: Last -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea190385-s8_inmedpharma.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 43735}]
metadata_filer: {"company-data": {"conformed-name": "InMed Pharmaceuticals Inc.", "cik": "0001728328", "assigned-sic": "2834", "organization-name": "03 Life Sciences", "irs-number": "000000000", "state-of-incorporation": "A1", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-276212", "film-number": "231506827"}, "business-address": {"street1": "SUITE 310, 815 W. HASTINGS STREET", "city": "VANCOUVER", "state": "A1", "zip": "V6C 1B4", "phone": "(604) 669-7207"}, "mail-address": {"street1": "SUITE 310, 815 W. HASTINGS STREET", "city": "VANCOUVER", "state": "A1", "zip": "V6C 1B4"}}
text: As filed with the Securities and Exchange Commission
  on December 21, 2023
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER
  THE SECURITIES ACT OF 1933
  INMED PHARMACEUTICALS
  INC.
  (Exact name of registrant as specified in its
  charter)
  British
      Columbia
  98-1428279
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S Employer
  Identification No.)
  Suite 310 – 815 West Hastings Street
  Vancouver, British Columbia V6C 1B4
  Canada
  Telephone: (604) 669-7207
  (Address, including zip code and telephone
  number, including area code, of registrant's principal executive offices)
  InMed Pharmaceuticals Inc. Amended 2017 Stock
  Option Plan
  (Full title of the plan)
  Registered Agent Solutions, Inc.
  1100 H Street NW
  Suite 840
  Washington, DC 20005
  Telephone: (888) 705-7274
  (Name, address, including zip code, and telephone
  number, including area code, of agent for service)
  Copies to:
  Eric A. Adams
  Chief Executive Officer
  InMed Pharmaceuticals Inc.
  Suite 310 – 815 West Hastings Street
  Vancouver, British Columbia V6C 1B4
  Canada
  Telephone: (604) 669-7207
  Brian P. Fenske
  Norton Rose Fulbright US LLP
  1301 McKinney, Suite 5100
  Houston, Texas 77010
  Telephone: (713) 651-5557
  Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of "large
  accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company"
  in in Rule 12b-2 of the Exchange Act.
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Non-accelerated filer
  ☒
  Smaller reporting company
  ☒
  Emerging growth company
  ☒
  If an emerging growth company, indicate by check mark if the registrant
  has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
  to Section 7(a)(2)(B) of the Securities Act. ☐
  EXPLANATORY NOTE
  On December 19, 2023, the board of directors of
  InMed Pharmaceuticals Inc. (the "Company"), approved the reservation of additional 700,000 shares of common stock, without
  par value (the "Common Shares"), for allotment under the InMed Pharmaceuticals Inc. Amended 2017 Stock Option Plan (the "2017
  Stock Option Plan").
  This Registration Statement on Form S-8 (this
  "Registration Statement") is being filed by the Company to register the additional Common Shares. These shares are in addition
  to the 51,633 Common Shares that may be issued under the 2017 Stock Option Plan pursuant to the Company's Registration Statements
  on Form S-8 (File No. 333-268356) filed with the Securities and Exchange Commission (the "Commission") on November 14,
  2022, Form S-8 (File No. 333-253912) filed with the Commission on March 5, 2021, and Form S-8 (File No. 333-260323) filed with the
  Commission on October 18, 2021 (collectively, the "Prior Registration Statements"). Pursuant to General Instruction E to
  Form S-8 under the Securities Act of 1933, as amended (the "Securities Act"), the contents of the Prior Registration Statements
  are incorporated by reference into this Registration Statement, except to the extent supplemented, amended and superseded by the information
  set forth herein.
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3. Incorporation of Documents by Reference.
  Except to the extent that information is deemed furnished and not
  filed pursuant to securities laws and regulations, the following documents, which have been previously filed with the Commission, are
  incorporated by reference into this Registration Statement:
  ●
  our
                                              Annual Report on
  Form
                                              10-K
  for the fiscal year ended June 30, 2023, filed with the SEC on September 29, 2023 and Amendment No.1 thereto on
  Form 10-K/A
  filed with the SEC on December 21, 2023;
  ●
  our
                                              Definitive Proxy Statement on
  Schedule
                                              14A
  , filed with the SEC on October 27, 2023;
  ●
  our
                                              Quarterly Report on
  Form
                                              10-Q
  for the quarter ended September 30, 2023, filed with the SEC on November 14, 2023;
                                              and
  ●
  our Current Reports on Form 8-K, filed with the SEC on
  July 20, 2023
  ,
  July 24, 2023
  ,
  September 8, 2023
  ,
  September
                                                                                                                                       25, 2023
  ,
  September
                                                                                                                                       25, 2023
  ,
  September 29,
                                                                                                                                       2023
  ,
  October 24,
                                                                                                                                       2023
  ,
  October
                                                                                                                                       30, 2023
  ,
  November
                                                                                                                                       2, 2023
  ,
  November 14,
                                                                                                                                       2023
  ,
  November
                                                                                                                                       29, 2023
  , and
  December 20, 2023
  .
  Except to the extent that information is deemed furnished and not
  filed pursuant to securities laws and regulations, all documents filed by the Company with the Commission pursuant to Sections 13(a),
  13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, after the date of this Registration Statement and prior to the
  filing of a post-effective amendment that (i) indicates that all securities offered under this Registration Statement have been sold,
  or (ii) deregisters all securities then remaining unsold under this Registration Statement, shall be deemed to be incorporated by reference
  into this Registration Statement and to be a part of this Registration Statement from the date of filing of such documents. In no event,
  however, will any information that we disclose under Item 2.02 or Item 7.01 (and any related exhibits) of any Current Report on Form
  8-K that we may from time to time furnish to the Commission be incorporated by reference into, or otherwise become a part of, this Registration
  Statement.
  For purposes of this Registration Statement, any statement contained
  in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded to the extent
  that a statement contained herein or in any subsequently filed document which also is or is deemed to be incorporated herein by reference
  modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded,
  to constitute a part of this Registration Statement.
  II-
  1
  ITEM 8.
  Exhibits.
  Exhibit No.
  Exhibit Description
  4.1
  Amended
      and Restated Articles (incorporated by reference to Exhibit 3.1 to the Registrant's Registration Statement on Form S-1 (File
      No. 333-239319), filed on June 19, 2020).
  4.2
  InMed
      Pharmaceuticals Inc. Amended 2017 Stock Option Plan (incorporated by reference to Exhibit 4.2 to the Registrant's Registration
      Statement on Form S-8 (File No. 333-253912) filed on March 5, 2021).
  4.3
  Form
      of Stock Option Agreement pursuant to InMed Pharmaceuticals Inc. Amended 2017 Stock Option Plan (incorporated by reference to Exhibit
      4.3 to the Registrant's Registration Statement on Form S-8 (File No. 333-253912) filed on March 5, 2021).
  4.4
  Form
      of Specific Common Share Certificate (incorporated by reference to Exhibit 4.3 to the Company's Form S-1 filed on July 13,
      2021).
  5.1*
  Opinion of Norton Rose Fulbright Canada LLP regarding legality of securities being registered.
  23.1*
  Consent of Marcum LLP, Independent Registered Public Accounting Firm.
  23.2*
  Consent of KPMG LLP, Independent Registered Public Accounting Firm.
  23.3*
  Consent of Norton Rose Fulbright Canada LLP (contained in Exhibit 5.1).
  24.1*
  Power of Attorney (included as part of signature page
      to this Registration Statement).
  107.1*
  Calculation of Filing Fee Tables
  *
  Filed herewith.
  II-
  2
  SIGNATURES
  Pursuant to the requirements of the Securities
  Act, InMed Pharmaceuticals Inc., certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
  on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in the City of Vancouver, British Columbia, Canada, on December 21, 2023.
  INMED PHARMACEUTICALS INC.
  By:
  /s/
  Eric A. Adams
  Eric A. Adams
  President and Chief Executive Officer
  POWER OF ATTORNEY
  KNOW ALL MEN BY THESE PRESENTS, that each person
  whose signature appears below, the undersigned officers and directors of InMed Pharmaceuticals Inc., hereby severally constitute and
  appoint Eric A. Adams and Jonathan Tegge, and each of them singly (with full power to each of them to act alone), his true and lawful
  attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead,
  and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and
  to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact
  and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done
  in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all
  that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done
  by virtue hereof.
  Pursuant to the requirements of the Securities
  Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated on December 21,
  2023.
  Name
  Title
  /s/ Eric A. Adams
  President, Chief Executive Officer and Director
  Eric A. Adams
  (principal executive officer)
  /s/ Jonathan Tegge
  Interim Chief Financial Officer
  Jonathan Tegge
  (principal financial officer and principal accounting officer)
  /s/ Janet Grove
  Director
  Janet Grove
  /s/
  Bryan Baldasare
  Director
  Bryan Baldasare
  /s/ Andrew Hull
  Director
  Andrew Hull
  /s/ Nicole Lemerond
  Director
  Nicole Lemerond
  II-
  3
  AUTHORIZED REPRESENTATIVE
  Pursuant to the requirements
  to Section 6(a) of the Securities Act of 1933, the undersigned has signed this registration statement solely in the capacity of the duly
  authorized representative of InMed Pharmaceuticals Inc. in the United States on December 21, 2023.
  By:
  /s/
  Andrew Hull
  Andrew Hull
  II-
  4